ArticleInternational journal of molecular sciences2019
IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients.
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- CNS tumor with EP300::BCOR fusion: discussing its prevalence in adult population.Acta neuropathologica communications · 2023Pooled it
- A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.Haematologica · 2026Article
- IGF-1R inhibitors in cancer: A review of available evidence and future outlook.Critical reviews in oncology/hematology · 2025Review
- BCOR loss promotes both retinoblastoma growth and susceptibility to IGF1R inhibition.Neuro-oncology · 2025Article
- A novel KDM2A::YAP1 fusion in a pediatric supratentorial CNS neoplasm resembling a tumor with BCOR internal tandem duplication.Free neuropathology · 2025Article
- Associations in cell type-specific hydroxymethylation and transcriptional alterations of pediatric central nervous system tumors.Nature communications · 2024Article
- Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Molecular dynamics simulation of the brain-isolated single-domain antibody/nanobody from camels throughFrontiers in molecular biosciences · 2024Article
- Hydroxymethylation alterations in progenitor-like cell types of pediatric central nervous system tumors are associated with cell type-specific transcriptional changes.Research square · 2023Article
- N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling.International journal of molecular sciences · 2022Article
- The Insulin Receptor: An Important Target for the Development of Novel Medicines and Pesticides.International journal of molecular sciences · 2022Review
- Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with aAJNR. American journal of neuroradiology · 2022Article
- BCOR Internal Tandem Duplication Expression in Neural Stem Cells Promotes Growth, Invasion, and Expression of PRC2 Targets.International journal of molecular sciences · 2021Article
- Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma.Cancers · 2021Article
- The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia.Frontiers in cell and developmental biology · 2021Review
- Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation.Genes & development · 2020Article
- Central nervous system high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR)-case-based reviews.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Review
- Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.Journal of hematology & oncology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 2 countries.
Nadine VewingerSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Nadine.Vewinger@unimedizin-mainz.de.
Sabrina HuprichSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. sabrina.huprich@gmx.de.
Larissa SeidmannInstitute of Pathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. larissa.seidmann@unimedizin-mainz.de.
Alexandra RussoSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Alexandra.Russo@unimedizin-mainz.de.
Francesca AltSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Francesca.Alt@unimedizin-mainz.de.
Hannah BenderSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Bender.hannah@gmail.com.
Clemens SommerInstitute of Neuropathology, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. clemens.sommer@unimedizin-mainz.de.
David SamuelDepartment of Oncology, Valley Children's Hospital, Madera, CA 93636, USA. DSamuel@valleychildrens.org.
Nadine LehmannSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Nadine.Lehmann@unimedizin-mainz.de.ORCID 0000-0003-1897-3129
Nora BackesSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Nora.Backes@unimedizin-mainz.de.
Lea RothSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Lea.Roth@unimedizin-mainz.de.
Patrick N HarterNeurological Institute (Edinger-Institute), Goethe-University Medical School, 60528 Frankfurt am Main, Germany and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 69120 Heidelberg, Germany, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. patrick.harter@kgu.de.
Katharina FilipskiNeurological Institute (Edinger-Institute), Goethe-University Medical School, 60528 Frankfurt am Main, Germany and German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 69120 Heidelberg, Germany, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. Katharina.Filipski@kgu.de.
Jörg FaberSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. Joerg.Faber@unimedizin-mainz.de.ORCID 0000-0002-5432-8234
Claudia ParetSection of Pediatric Oncology, Children's Hospital, University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany. claudia.paret@unimedizin-mainz.de.ORCID 0000-0002-9094-1634
Johannes Gutenberg University Mainz · DEGerman Cancer Research Center · DEGoethe University Frankfurt · DEChildren's Hospital Central California · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1)
Indexed as
Antineoplastic AgentsBrain NeoplasmsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMaleMolecular Targeted TherapyNeoplasms, NeuroepithelialProto-Oncogene ProteinsPyrimidinesReceptor, IGF Type 1Receptors, SomatomedinRepressor ProteinsSulfonesAntineoplastic AgentsBCOR protein, humanceritinibIGF1R protein, humanIGF2 protein, humanInsulin-Like Growth Factor IIProto-Oncogene ProteinsPyrimidinesReceptor, IGF Type 1Receptors, SomatomedinRepressor ProteinsSulfonesVinblastineceritinibHGNET-BCORIGF1RIGF2vinblastine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.